GLP-1 (semaglutide or tirzepatide) Therapy in Older Adults: Balancing Benefit & Risk Beyond Age 65
- Joshua Silva, MD
- Dec 12
- 5 min read
Updated: 2 days ago
Many discussions about GLP-1 medications in older adults come from friends, family, or acquaintances, as well as online forums, news stories, and social media posts. While these conversations often come from good intentions, they can spread partial or misleading information — especially about safety, dosing, or who these medications are “meant for.” Some people may hear that GLP-1s are too risky for older adults, while others are told they’re a universal solution for aging or weight management. In truth, the safest and most effective use depends on careful evaluation, appropriate dosing, and ongoing medical oversight.
At Potere Health MD, serving St. George, Cedar City, and Salt Lake City, Utah, our physician-supervised weight-management programs emphasize science-based, individualized care for adults at every stage of life. Every treatment recommendation — including the use of GLP-1 or GLP-1/GIP therapies — is guided by clinical research, patient safety, and functional outcomes. Our goal is to help older adults achieve metabolic health improvements while maintaining muscle, nutrition, and independence, with decisions grounded in evidence, not anecdotes.
Why GLP-1 (semaglutide or tirzepatide) Might Be Particularly Relevant in Older Adults
Cardiometabolic protection
Large cardiovascular outcome trials (e.g., SELECT, SUSTAIN-6) show semaglutide reduces major adverse cardiovascular events (MACE), and subgroup analyses suggest these benefits extend to older patients.
Improve hemoglobin A1C (blood sugar) without the risk of hypoglycemia
Unlike insulin and sulfonylureas, GLP-1 medications (semaglutide or tirzepatide) lowers blood sugar in a glucose-dependentmanner. This means it reduces blood glucose only when levels are elevated, significantly decreasing the risk of hypoglycemia (low blood sugar) and its associated symptoms — a major advantage for older adults, who may be more sensitive to hypoglycemia.
Weight & metabolic improvement
GLP-1 medications (semaglutide or tirzepatide) produces clinically meaningful weight loss while also improving blood pressure, cholesterol, inflammation, and glycemic control. Together, these changes reduce cardiometabolic risk and may improve overall quality of life by addressing multiple health factors at once.
Key Risks & Considerations for Adults Over 65
Gastrointestinal intolerance and dehydration
Older adults are more sensitive to the gastrointestinal side effects of GLP-1 medications (semaglutide or tirzepatide), such as nausea, vomiting, and diarrhea. If not monitored, these effects can lead to volume depletion and dehydration— known risk factors for kidney injury and falls.
Sarcopenia (loss of muscle mass due to normal aging) & osteoporosis (bone density loss)
Older adults are at an increase risk of sarcopenia and osteopenia/osteoporosis. Rapid or extreme Weight loss can accelerate lean mass and bone density decline, potentially increasing frailty and fracture risk.
Do the Benefits Outweigh the Risks?
When deciding whether to use GLP-1 (semaglutide or tirzepatide) therapy in adults over 65, the essential question is the same as with any medication: do the benefits outweigh the risks?
For most older adults with obesity, type 2 diabetes, or cardiovascular disease, the benefits are substantial — but the potential risks must also be considered:
Benefits: cardiovascular protection, significant weight loss, improved glucose control, blood pressure, and inflammation, with a lower risk of hypoglycemia compared to many older therapies.
Risks: gastrointestinal (GI) side effects, dehydration (which may contribute to kidney injury and orthostatic hypotension), sarcopenia, and osteoporosis.
Protecting Muscle & Bone Health While on GLP-1 (semaglutide or tirzepatide) Therapy
Protein – Protect against sarcopenia
Target 1.0–1.2 g/kg/day (e.g., 70–90 g for a 75-kg adult).
Spread protein across meals for better absorption.
Resistance & weight-bearing exercise – Protection against sarcopenia and osteopenia/osteoporosis
Strength training at least twice per week, plus walking, stair climbing, or light impact activity if safe.
Bone health support
Calcium 1,000–1,200 mg/day (diet or supplements).
Vitamin D 600–800 IU/day to maintain 25-OH vitamin D >30 ng/mL.
Consider DEXA scans for baseline and follow-up in those with osteopenia or osteoporosis.
Monitoring
Assess hydration to preserve kidney function and prevent hypotension.
Slow titration if rapid weight loss threatens lean mass or nutrition.
Practical Prescribing Tips
Start low and go slow with titration.
Monitor renal labs and hydration status.
Encourage nutrition and exercise support to preserve muscle and bone.
Reassess therapy if frailty or falls risk emerges.
Bottom line: GLP-1 (semaglutide or tirzepatide) therapy can be highly valuable for older adults when used thoughtfully — with attention to pre-existing conditions, individualized dose adjustments, and proactive risk mitigation strategies.
At Potere Health MD, every aspect of your weight-loss care—education, guidance, and decision-making—is grounded in clinical research, not marketing trends. We help patients across St George, Cedar City, and Salt Lake City Utah achieve healthy, sustainable weight control through physician-supervised GLP-1 and GIP programs that emphasize evidence, safety, and lasting results.
Disclaimer
This article is for educational purposes only and is not a substitute for medical advice. Individual care decisions should be made in consultation with a licensed clinician.
About the Author
Dr. Joshua Silva, MD, is a licensed physician and Medical Director of Potere Health MD. After graduating medical school from the University of Hawaii, he completed residency training in Occupational and Environmental Medicine from the University of Utah where he also earned a master's degree in Occupation Health. He now specializes in evidence-based weight management, including GLP-1/GIP therapies (semaglutide & tirzepatide). Dr. Silva provides in-person and virtual care for patients with clinics in Salt Lake City, St. George, and Cedar City, Utah.
Sources:
Liabeuf S, Minutolo R, Floege J, Zoccali C. The use of SGLT2 inhibitors and GLP-1 receptor agonists in older patients: a debate on approaches in CKD and non-CKD populations. Clin Kidney J. 2025;18(2):sfae380. doi:10.1093/ckj/sfae380.
Dadwani RS, Wan W, Skandari MR, Huang ES. Expected health benefits of SGLT-2 inhibitors and GLP-1 receptor agonists in older adults. MDM Policy Pract. 2023;8(2):23814683231187566. doi:10.1177/23814683231187566.
Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC10363885/
Henney AE, Wilding JPH, Alam U, Cuthbertson DJ. Obesity pharmacotherapy in older adults: a narrative review of evidence. Int J Obes (Lond). 2025;49(3):369-380. doi:10.1038/s41366-024-01529-z.
Available at: https://www.nature.com/articles/s41366-024-01529-z
Gorgojo-Martínez JJ, Mezquita-Raya P, Carretero-Gómez J, et al. Clinical recommendations to manage gastrointestinal adverse events in patients treated with GLP-1 receptor agonists: a multidisciplinary expert consensus. J Clin Med.2022;12(1):145. doi:10.3390/jcm12010145.
Available at: https://www.mdpi.com/2077-0383/12/1/145
U.S. Preventive Services Task Force. Draft Recommendation: Vitamin D and Calcium Combined Supplementation for the Primary Prevention of Falls and Fractures in Community-Dwelling Adults.
Milliman Inc. Medicare Cost of Osteoporotic Fractures. 2021.
Nowson CA, O’Connell SL, et al. Protein requirements and recommendations for older people: a review. Nutrients.2015;7(8):6874-6899. doi:10.3390/nu7085311.
Available at: https://www.mdpi.com/2072-6643/7/8/5311
Putra C, Konow N, Gage M, et al. Protein source and muscle health in older adults. Nutrients. 2021;13(7):2250. doi:10.3390/nu13072250.
Available at: https://pubmed.ncbi.nlm.nih.gov/33652669/
Comments